Show simple item record

dc.contributor.authorGarcía-Romero, N
dc.contributor.authorPalacín-Aliana, I
dc.contributor.authorMadurga, R
dc.contributor.authorCarrión-Navarro, J
dc.contributor.authorEsteban-Rubio, Susana
dc.contributor.authorJiménez, B
dc.contributor.authorCollazo, A
dc.contributor.authorPérez-Rodríguez, F
dc.contributor.authorOrtiz de Mendivil, A
dc.contributor.authorFernández-Carballal, C
dc.contributor.authorGarcía-Duque, S
dc.contributor.authorDiamantopoulos-Fernández, J
dc.contributor.authorBelda-Iniesta, Cristobal 
dc.contributor.authorPrat-Acín, R
dc.contributor.authorCalvo, E
dc.contributor.authorAyuso-Sacido, A
dc.contributor.authorSanchez-Gomez, Pilar 
dc.date.accessioned2020-09-07T19:28:27Z
dc.date.available2020-09-07T19:28:27Z
dc.date.issued2020-06-22
dc.identifier.citationBMC Med . 2020 Jun 22;18(1):142.es_ES
dc.identifier.issn1741-7015es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/10986
dc.description.abstractGlioblastoma (GBM) is one of the most aggressive and vascularized brain tumors in adults, with a median survival of 20.9 months. In newly diagnosed and recurrent GBM, bevacizumab demonstrated an increase in progression-free survival, but not in overall survival. We conducted an in silico analysis of VEGF expression, in a cohort of 1082 glioma patients. Then, to determine whether appropriate bevacizumab dose adjustment could increase the anti-angiogenic response, we used in vitro and in vivo GBM models. Additionally, we analyzed VEGFA expression in tissue, serum, and plasma in a cohort of GBM patients before and during bevacizumab treatment. We identified that 20% of primary GBM did not express VEGFA suggesting that these patients would probably not respond to bevacizumab therapy as we proved in vitro and in vivo. We found that a specific dose of bevacizumab calculated based on VEGFA expression levels increases the response to treatment in cell culture and serum samples from mice bearing GBM tumors. Additionally, in a cohort of GBM patients, we observed a correlation of VEGFA levels in serum, but not in plasma, with bevacizumab treatment performance. Our data suggest that bevacizumab dose adjustment could improve clinical outcomes in Glioblastoma treatment.es_ES
dc.description.sponsorshipThis work was supported by grants from the “Fondo de Investigaciones Sanitarias” (FIS) (PI17-01489), the Miguel Servet Program (CP11/00147) del Instituto de Salud Carlos III (AAS), and the Ministerio de Economía y Competitividad–FEDERER (RTC-2016-4990-1). IPA was supported by “Ayudas para la contratación de ayudantes de investigación cofinanciadas por el Fondo Social Europeo a través del Programa Operativo de Empleo Juvenil y la Iniciativa de Empleo Juvenil (YEI),” and SER was supported by FPI-CEU predoctoral fellowship.es_ES
dc.language.isoenges_ES
dc.publisherBMCes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAngiogenesises_ES
dc.subject.meshBevacizumabes_ES
dc.subject.meshGlioblastomaes_ES
dc.subject.meshNeovasculogenesises_ES
dc.subject.meshVEGFAes_ES
dc.titleBevacizumab dose adjustment to improve clinical outcomes of glioblastoma.es_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID32564774es_ES
dc.format.volume18es_ES
dc.format.number1es_ES
dc.format.page142es_ES
dc.identifier.doi10.1186/s12916-020-01610-0es_ES
dc.contributor.funderFondo de Investigaciones Sanitariases_ES
dc.contributor.funderInstituto de Salud Carlos III - ISCIIIes_ES
dc.contributor.funderEuropean Regional Development Fund (ERDF/FEDER)es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1741-7015es_ES
dc.relation.publisherversionhttps://doi.org/10.1186/s12916-020-01610-0es_ES
dc.identifier.journalBMC medicinees_ES
dc.repisalud.centroISCIII::Unidad Funcional de Investigación de Enfermedades Crónicas (UFIEC)es_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI17-01489es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/CP11/00147es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/RTC-2016-4990-1es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional